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The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial new evidence on locoregional
and systemic therapies for early breast cancer. Further experience has supported the adequacy of tumor margins
deﬁned as ‘no ink on invasive tumor or DCIS’ and the safety of omitting axillary dissection in speciﬁc cohorts.
Radiotherapy trials support irradiation of regional nodes in node-positive disease. Considering subdivisions within
luminal disease, the Panel was more concerned with indications for the use of speciﬁc therapies, rather than surrogate
identiﬁcation of intrinsic subtypes as measured by multiparameter molecular tests. For the treatment of HER2-positive
disease in patients with node-negative cancers up to 1 cm, the Panel endorsed a simpliﬁed regimen comprising pacli-
taxel and trastuzumab without anthracycline as adjuvant therapy. For premenopausal patients with endocrine respon-
sive disease, the Panel endorsed the role of ovarian function suppression with either tamoxifen or exemestane for
patients at higher risk. The Panel noted the value of an LHRH agonist given during chemotherapy for premenopausal
women with ER-negative disease in protecting against premature ovarian failure and preserving fertility. The Panel noted
increasing evidence for the prognostic value of commonly used multiparameter molecular markers, some of which also
carried prognostic information for late relapse. The Panel noted that the results of such tests, where available, were fre-
quently used to assist decisions about the inclusion of cytotoxic chemotherapy in the treatment of patients with luminal
disease, but noted that threshold values had not been established for this purpose for any of these tests. Multiparameter
molecular assays are expensive and therefore unavailable in much of the world. The majority of new breast cancer cases
and breast cancer deaths now occur in less developed regions of the world. In these areas, less expensive pathology
tests may provide valuable information. The Panel recommendations on treatment are not intended to apply to all
patients, but rather to establish norms appropriate for the majority. Again, economic considerations may require that
less expensive and only marginally less effective therapies may be necessary in less resourced areas. Panel recommen-
dations do not imply unanimous agreement among Panel members. Indeed, very few of the 200 questions received
100% agreement from the Panel. In the text below, wording is intended to convey the strength of Panel support for each
recommendation, while details of Panel voting on each question are available in supplementary Appendix S2, available
at Annals of Oncology online.
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introduction
The fourteenth St Gallen International Breast Cancer Conference,
held for the ﬁrst time in neighboring Vienna, Austria, conﬁrmed,
and extended the recommendations of earlier reports.
This report is focused on providing a practical approach to
the allocation of available therapies to individual patients in the†See Appendix for the list of Panel Members.
*Correspondence to: Prof. Aron Goldhirsch, Program of Breast Health (Senology), European
Institute of Oncology, Via Ripamonti 435, Milan 20141, Italy. Tel: +39-02-57489439,
Fax: +39-02-94379273, E-mail aron.goldhirsch@ibcsg.org, aaron.goldhirsch@ieo.it
sp
ec
ia
la
rt
ic
le
s
special articles Annals of Oncology 26: 1533–1546, 2015doi:10.1093/annonc/mdv221
Published online 4 May 2015
© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact jour-
nals.permissions@oup.com
light of the most recent and reliable information from clinical
trials, laboratory insights and the expert opinions of a large inter-
national faculty. To this end, attention is given to tumor factors
and the condition of the host. Tumor factors are primarily the
presence or absence of targetable features such as hormone recep-
tors and HER2, and the metastatic potential, as reﬂected in mea-
sures of proliferation and anatomic extent of disease. Patient
factors include menopausal status, age, comorbidity, and patient
preference.
St Gallen 2015: news and progress
A large part of the world has an increasing incidence of breast
cancer, but limited resources to treat it. The majority of new
cases and the majority of breast cancer deaths now occur in
less developed regions of the world [1]. Many of the countries
in the less developed regions have low health expenditure per
capita, which renders the use of expensive laboratory tests and
treatments inaccessible to the majority of patients worldwide
(http://data.worldbank.org/indicator/SH.XPD.PCAP?display=map
accessed 29.12.2014). The development of effective treatments
which are less expensive is thus a priority [2].
The Panel welcomed a number of recent clinical trial results,
especially the SOFT and TEXT trials clarifying the role of ovarian
function suppression with tamoxifen or exemestane in the endo-
crine treatment of premenopausal patients, and the POEMS trial
conﬁrming the protective value of an LHRH agonist for ovarian
function [3–5]. A curious paradox emerged in the evidence for
local therapies. Surgical management continued its trend to less
extensive surgery without compromise of the outcome [6, 7], but
recent radiotherapy trials in node-positive disease found superior
disease control with extended radiation ﬁelds which included
regional lymph node areas [8, 9]. No such beneﬁt was seen in a
population-based study [10]. Hypofractionated shorter course
radiotherapy has become accepted as a standard option [11, 12]
offering increased patient convenience and reduced resource
usage.
A recent update of the overview of adjuvant aromatase inhibi-
tors (AIs) (Dowsett M, personal communication) in postmeno-
pausal patients found that, on average, patients have fewer
recurrences while assigned AI than while assigned tamoxifen
during those periods when the treatments differed, although
there was no signiﬁcant difference in breast cancer mortality in
trials comparing 5 years of an AI to the sequence of tamoxifen
followed by an AI.
breast cancer subtypes
Extensive genomic analysis of breast cancers discloses four
coherent groups [13], similar to the intrinsic subtypes deﬁned
by gene expression proﬁling [14]. Subtypes can be deﬁned by
multiparameter molecular tests such as the PAM-50 [15] or
MammaPrint/BluePrint [16]. However, in clinical practice, the
key question is not the separation of the molecularly deﬁned
intrinsic subtypes, but the discrimination between patients
who will or will not beneﬁt from particular therapies. Several of
the multiparameter molecular markers have been used for this
purpose [17, 18]. Because in much of the world, such tests
may not be available for logistic or ﬁnancial reasons, surrogate
approaches have been developed using more widely available
immunohistochemical (IHC) tests for estrogen receptor, proges-
terone receptor together with IHC or in situ hybridization tests
for HER2 overexpression or ampliﬁcation. Ki-67 is used as an
alternative marker of proliferation albeit with lesser analytical
validity than molecular testing [19, 20].
Standard pathological features seem adequate to deﬁne clinic-
ally useful groups such as triple-negative, hormone receptor-
negative and HER2-positive and hormone receptor-positive\and
HER2-positive tumors for which treatment recommendations
are seldom controversial. It is among the patients with ‘luminal’
disease, deﬁned by the presence of ER and/or PgR and negative
HER2, that uncertainty about optimal treatment most common-
ly arises, as clinicians seek to avoid overtreatment and under-
treatment. A survey of patterns of the use of chemotherapy in
such patients [21, 22] showed that there was a substantially
different use of chemotherapy in different geographical areas.
The various multiparameter molecular marker assays all
include genes reﬂecting proliferative activity: indeed, it has been
suggested that the majority of the prognostic information in
these tests comes from the proliferative genes included [23].
IHC measurement of proliferative activity using the Ki-67 assay
has proved controversial. There can be little doubt that Ki-67
scores carry robust prognostic information [24], and that high
values predict the beneﬁt of addition of cytotoxic chemotherapy
[25], but deﬁnition of a single useful cut point has proved
elusive both because Ki-67 displays a continuous distribution
[26], and as a result of analytic and preanalytic barriers to stan-
dardized assessment [27]. Other news presented at the meeting
is summarized in Table 1.
panel deliberations
On the Saturday morning, the Panel reviewed a series of some
200 questions developed by iterative consultation over the
months preceding the conference. Voting on most questions was
in the format yes, no, or abstain, with some presented as multiple
mutually exclusive alternatives. Abstaining was recommended
if a Panel member had a conﬂict of interest, felt that there was in-
sufﬁcient evidence to support an opinion or that he or she lacked
the relevant expertise. Detailed voting records for each of the
questions put to the Panel are provided in the supplementary
Appendix S2, available at Annals of Oncology online.
surgery of the primary
The Panel strongly endorsed recent ﬁndings that the minimal ac-
ceptable surgical margin was ‘no ink on invasive tumor or DCIS’.
This conclusion applies regardless of tumor characteristics such
as lobular histology, extensive intraductal component, young age,
multifocality or multicentricity, and unfavorable biological
subtype [7].
A clear majority of the Panel agreed that multifocal and mul-
ticentric tumors could be treated with breast conservation, pro-
vided the above margin clearance was obtained and whole-
breast radiotherapy was planned.
Following neoadjuvant chemotherapy, the Panel did not con-
sider it necessary to resect the entire area of the original primary
if downstaging had occurred.
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Table 1. Recent research findings presented at the 14th International Conference on Primary Therapy of Early Breast Cancer and their implications
for patient care
Field or treatment Status of research/implications for patient care
Surgical management Local regional recurrence is becoming less frequent over recent decades [28]. Meta-analysis of surgical
series showed no further benefit from margins beyond ‘no ink on invasive tumor or DCIS’ [29]. This
conclusion applies regardless of tumor characteristics such as lobular histology, extensive intraductal
component, young age, and unfavorable biological subtype [7].
Avoiding axillary dissection for patients with one or two macrometastatic lymph nodes [30, 31] proved
safe in a large institutional series, confirming the applicability of randomized trial approaches
(ACOSOG Z011, AMAROS) for the majority of women with T1 and T2 clinically node-negative
breast cancer [6].
Extent of locoregional radiotherapy Two recent radiotherapy trials in node-positive disease found superior disease control with extended
radiation fields which included regional lymph node areas [8, 9].
Prognostic value of multiparameter molecular
markers
Oncotype DX® was predictive of late distant recurrence in NSABP B-14 [32]. However, it was not
predictive of late distant recurrence after endocrine therapy in the ATAC study, while PAM-50 ROR
score® [17, 33] and the immunohistochemically based IHC4® each remained prognostically significant
beyond 5 years of endocrine treatment [34, 35]. Likewise, EndoPredict® was prognostically significant
beyond 5 years in ABCSG trials 6 and 8, particularly when combined with clinical factors [36]. Breast
Cancer Index® was prognostic for early and late distant recurrence in two series [37].
Reducing the risk of chemotherapy-induced
premature ovarian failure
In the recently reported POEMS study [5], OFS with LHRH analogue during chemotherapy for patients
with receptor-negative breast cancer reduced the incidence of premature ovarian failure, confirming
the report of Del Mastro et al. [38], but contrary to the findings of the ZORO study of the German
Breast Group [39]. In the POEMS study, such treatment also increased the rate of subsequent
successful pregnancies and did not compromise disease outcomes [5].
Observational registry data Because only a small fraction of patients are entered on randomized clinical trials, evolving standardized
registry datasets offer information which may be more typical of the entire patient population.
Although biases can never be entirely removed from such datasets, useful information has been
described in many clinical settings including oncology [40].
Cancer genomics Multiple recent studies have described the landscape of the expanding list of mutations and other
genetic abnormalities in patients with recurrent breast cancer. Apart from a small number of
frequently mutated genes, there is a long ‘tail’ of genetic abnormalities, which are infrequent but may
cluster in particular pathways such as the JUN kinase pathway [41].
Genomic tools for marker assessment Genomic tests added little to IHC for the assessment of ER and only slightly more for PgR, while there
was more substantial disagreement between conventional and genomic testing for HER2 [42, 43].
Intrinsic subtypes Attempts to reproduce the intrinsic subtype distinction between ‘luminal A-like’ and ‘luminal B-like’
using conventional pathology have proved impractical. While it is possible to refine definitions to
more closely approximate intrinsic subtypes [19, 44, 45], this may not provide the clinically useful
threshold to guide treatment choice.
Intrinsic subtypes within HER2-positive disease are heterogeneous and, in one study, this was reflected
in potential differences in predicting degree of response to trastuzumab [46]. The difference between
the hormone receptor-negative and positive cohorts within HER2-positive disease is illustrated by the
consistently higher clinical response (pCR) to neoadjuvant therapies for the hormone receptor-
negative cohort [47, 48].
Although a majority of triple-negative breast cancers show the basal-like subtype [49], the distinction
between these and other types of triple-negative breast cancer is important for choice of
chemotherapy in that carboplatin is as effective as docetaxel in basal-like but less so in other intrinsic
subtypes in the metastatic setting [50]. Further dissection of subtypes within triple-negative breast
cancer reveals seven distinct groupings, which differ markedly in their clinical response to
neoadjuvant chemotherapy [51]. Preclinical studies also show heterogeneity of response to other
agents in cell lines of the different triple-negative subtypes [52], though this subclassification is not yet
ready for clinical application.
Tumour-infiltrating lymphocytes (TILs) TILs are most often found in triple-negative (TN), HER2-positive, and other highly proliferative breast
cancers, and have been associated with increased pCR, longer disease-free survival (DFS), and
improved overall survival (OS), independent of other prognostic factors [53, 54] in some studies,
though not among patients treated with trastuzumab in the N9831 trial [55].
Continued
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Table 1. Continued
Field or treatment Status of research/implications for patient care
Immune-related pathways Preclinical studies underline the importance of inflammation and the immune landscape in the stroma,
and point to the additional benefit of combining treatments aimed at the immune system (such as anti-
IL6) with small molecules such as gefitinib, which inhibit the EGF receptor otherwise enhanced [56].
Immune-targeted drugs may be useful, with recent data available on PD-1 inhibition [57–59].
Targeting CDK 4/6 Palbociclib, a CDK 4/6 inhibitor, given with letrozole showed superior clinical efficacy when compared
with letrozole alone as first-line treatment in the PALOMA-1/TRIO-18 randomized phase II trial in
metastatic breast cancer [60].
Targeting DNA repair pathways Patients with deficient DNA repair based on BRCA 1 or BRCA 2 mutation showed high pCR rates to
platinum salts [61, 62], and carboplatin is significantly more active than doctaxel in patients with
BRCA mutations treated in the metastatic setting [63].
Targeting the PI3K pathway The combination of the PIK3CA-alpha-specific inhibitor BYL719 and fulvestrant appears synergistic in
preclinical models [64].
Targeting the FGFR pathway Preliminary studies with the FGFR inhibitors dovitinib [65] and lucitanib [66] show promising response
rates but substantial toxicity.
Germline genetics In a small observational study, tamoxifen was associated with a reduced risk of contralateral breast
cancer in patients with BRCA 1 and BRCA 2 mutations where the index cancer was ER-positive or
ER-negative [67].
Primary prevention Recent data have emphasized the role of previous benign pathology with atypia and (although to a lesser
extent) even without atypia as a risk factor for breast cancer incidence [68].
ER and PgR testing A large single-institution experience suggests that equivocal ER staining between 1% and 9%, more
commonly seen among young patients, those with higher grade or HER2-positive or PgR-negative
tumors, tracks prognostically more closely with ER absent disease in terms of recurrence-free survival
[69]. Since these patients did not receive endocrine therapy, information is not available on the
predictive value of these equivocal ER levels.
Overcoming endocrine therapy resistance Combining endocrine agents and blockers of growth factors might be a useful strategy to reverse
estrogen receptor-targeted therapy resistance [70].
Ki-67 determination Extensive studies support the prognostic value of Ki-67, but clinical validation has proved difficult.
While high and low values are reproducible and clinically useful, there appears to be no optimal cut
point, at least to predict pCR along the continuum of Ki-67 levels [71, 72]. International collaboration
has led to improvements in concordance of the Ki-67 scoring [27, 73]. Image analysis may help to
reduce variability [74].
Neoadjuvant systemic therapies An improved pCR rate was observed with carboplatin for patients with triple-negative disease [75, 76].
Such improvement was not observed for HER2-positive disease [50, 76].
An improved pCR rate was also observed in triple-negative breast cancer using nab-paclitaxel instead of
solvent-based paclitaxel [50].
pCR rates were higher in patients with lymphocyte predominant breast cancer, either triple-negative or
HER2-positive, who were treated with carboplatin [77].
PIK3CA mutation was associated with inferior pCR rates to anti-HER2 therapies in several neoadjuvant
studies [78–80].
Neoadjuvant endocrine therapies usually take longer to achieve tumor response and pCR rates are
generally low. Treatment may continue until maximal response [81]. However, failure to lower Ki-67
offers early identification of a group of patients who should be considered for switch to alternative
therapies [82, 83].
Although the neoadjuvant neo-ALTTO trial was clearly positive and supported dual HER2 blockade
[84], the adjuvant ALTTO study (using a variety of different chemotherapy regimens) [85] is widely
regarded as negative. These apparently conflicting results may not be as divergent as commonly
perceived [86]. The hazard ratio in ALTTO of 0.84 comparing dual-blockade with trastuzumab alone
[85] was much as expected [86] and the P value of 0.048 is interpreted as nonsignificant because the
statistical analysis plan divided alpha between the dual-inhibition comparison and that involving the
sequential administration of trastuzumab and lapatinib.
Continued
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Table 1. Continued
Field or treatment Status of research/implications for patient care
Surgery A large US population-based study of more than 200 000 women noted that 7% underwent contralateral
prophylactic mastectomy (CPM). Although a small survival benefit was observed [87], information was not
available on BRCA status, which is known to be both a motivation for CPM and a marker for increased
benefit from such surgery. Thus, selection bias could not be adequately addressed in this registry study [88].
There has been a substantial increase in the use of CPM over the past two decades in the United States,
particularly in women <40 [89]. In Europe, the trend is less marked [90, 91].
Sentinel node biopsy is feasible and accurate after neoadjuvant chemotherapy and allows precise assessment
of pCR [92–95]. In patients with nodal involvement at presentation, the false-negative rate of sentinel node
biopsy is highly correlated with the number of sentinel nodes retrieved.
Breast conservation after neoadjuvant chemotherapy is feasible even when the disease is multifocal or
multicentric, provided that the margins are free of disease [96].
Radiation therapy Two trials on hypofractionated radiotherapy to the conserved breast examined essentially similar
regimens [11, 12]. Hypofractioned regimens involving 15 or 16 fractions are now widely accepted as
standard of care [97, 98]. Observational data from a population-based registry suggest that
radiotherapy to the internal mammary nodes may be associated with a survival benefit in node-
positive breast cancer [99].
Adjuvant systemic endocrine therapies in
premenopausal patients
For premenopausal women with endocrine responsive disease, results from the SOFT and TEXT trials
indicate that the combination of OFS (mainly using triptorelin) and tamoxifen or OFS and AI should
be considered for women at higher risk of recurrence such as those remaining premenopausal after
chemotherapy; those with multiple positive nodes; and those aged under 35 with appropriate disease-
associated risks [3, 4]. Given the potential long-term toxicity of OFS and the lack of a demonstrated
survival advantage for this strategy to date and indeed an adverse overall survival finding in ABCSG
12 using anastrozole [100], patient preference and treatment tolerance should be strongly considered
in initial and subsequent decisions regarding OFS.
Patient-reported outcomes in three endocrine therapy studies [101–103] showed distinct and substantial
impact on vasomotor, menopausal, and sexual symptoms. There was no difference seen in overall
measures of quality of life between the various therapies.
A composite risk score was developed for premenopausal patients in the SOFT and TEXT trials and
demonstrated that more intensive therapies such as OFS and exemestane were particularly beneficial
for patients at higher risk [104].
Adjuvant systemic endocrine therapies in
postmenopausal patients
In BIG 1–98, the original composite risk score which predicted 5-year DFS [105] was also prognostic for
disease outcomes beyond 5 years. Late recurrences did not vary according to treatment allocation
during the first 5 years [104].
Lifestyle and obesity Obesity has been associated with poor breast cancer outcomes.
The use of anastrozole (but not letrozole) in the adjuvant or extended adjuvant setting may be associated
with less benefit in obese women [106].
Adjuvant systemic cytotoxic chemotherapy A study in patients not selected on the basis of hormone receptor, HER2 or menopausal status with 0–3
lymph nodes involved, showed no advantage for six cycles compared with four of the same regimen [107].
A study of bone marrow neoplasms following systemic breast cancer therapy showed a slightly higher
incidence (0.4%–0.5% at 10 years) than had previously been appreciated [108].
Neurotoxicity was present at the completion of taxane-based chemotherapy in one-quarter of patients, and
one-third of these had persistent symptoms 1–3 years later [109].
The incidence of cardiac toxicity following chemotherapy and anti-HER2 treatment with trastuzumab did
not increase with extended follow-up in the HERA trial [110].
Adjuvant anti-HER2 therapy A phase II study of adjuvant paclitaxel and trastuzumab, without anthracycline, showed excellent
outcome in node-negative, HER2-positive, pT1b and pT1c tumors. Despite the absence of a control
group in this study, the regimen is now widely accepted as a standard of care for patients with small,
node-negative, HER2-positive tumors [111].
Young women Age was neither prognostic nor predictive for the impact of trastuzumab in the HERA trial [91].
LHRH agonist therapy during chemotherapy proved effective to protect against premature ovarian
failure and preserve fertility in young women with ER-negative breast cancer undergoing
chemotherapy [5, 112].
A global observational trial to assess the safety of interrupting endocrine therapy to allow attempted
pregnancy is in progress [112].
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surgery of the axilla
In the light of recent trial results, the Panel considered the situ-
ation of patients with macrometastases in one or two sentinel
nodes. The Panel was unanimous that following mastectomy
such patients required axillary dissection if no radiotherapy were
planned, but was almost exactly equally divided if mastectomy
were to be followed by radiotherapy. A clear majority of the Panel
would accept the omission of axillary dissection following conser-
vative resection with standard tangent radiotherapy planned, and
virtually all would do so if the radiotherapy were planned to use
high tangents including the lower axilla.
In a patient clinically node positive at presentation who
downstages after neoadjuvant chemotherapy, the Panel con-
sidered that sentinel node biopsy was appropriate, but that,
in this situation, axillary lymph node dissection was required
if even one sentinel node were positive. False-negative rates,
however, remain high unless three or more sentinel nodes
are examined.
radiation therapy
Radiotherapy courses involving hypofractionation were consid-
ered appropriate irrespective of age for patients without prior
chemotherapy or clinical lymph node involvement. A bare ma-
jority of the Panel would accept hypofractionated radiotherapy
for patients with axillary lymph node involvement or prior
chemotherapy.
Following breast-conserving surgery, the Panel considered
that radiation should be limited to breast only if the nodes
were negative. The Panel was in favor of at least some regional
nodal radiotherapy if the axillary nodes were positive, and a sub-
stantial minority would extend this to include the internal
mammary nodes [99]. In post-meeting discussions, several
Panel members suggested that adverse pathology should identify
patients with lower nodal burden requiring radiotherapy.
Following mastectomy, the Panel considered that radiother-
apy should be standard for patients with tumor size 5 cm or
greater, those with a positive macrometastatic sentinel node
biopsy but no axillary dissection, and for patients with one to
three involved nodes and adverse pathology. In the absence of
adverse pathology, patients with one to three involved nodes
could be treated without post mastectomy radiotherapy, though
a slim majority would include such treatment of patients aged
<40 years. The Panel considered that the same indications for
radiotherapy as described above applied after axillary dissection
without prior sentinel node biopsy even if less than eight nodes
were examined.
If given, the Panel felt that post mastectomy radiotherapy
should include the chest wall and regional nodes with most of
those voting prepared to omit the internal mammary nodes.
After immediate breast reconstruction, the Panel felt that radio-
therapy should include the lymph nodes and the reconstructed
breast in most cases.
Interestingly, although the Panel did not consider that surgi-
cal resection of the original area of tumor was necessary after
downstaging with neoadjuvant systemic therapy, they did con-
sider that radiotherapy following neoadjuvant chemotherapy
should in general be directed to the extent of disease before such
therapy.
pathology
As in previous St Gallen meetings, the Panel was of the strong
opinion that the distinction between strongly endocrine respon-
sive, low proliferation, good prognosis ‘luminal A-like’ and less
endocrine responsive, higher proliferation, poorer prognosis
‘luminal B-like’ (HER2-negative) tumors could be derived from
IHC tests for ER, PgR and Ki-67, though the use of Ki-67
required knowledge of local laboratory values. (The Panel used
these terms as a shorthand in classifying hormone receptor-
positive disease into luminal A-like and luminal B-like subsets,
though it recognized that IHC tests do not accurately measure
true intrinsic subtypes.) The corollary was that a clear majority
of the Panel did not believe that multiparameter molecular
markers were required for this distinction. A majority of the
Panel was prepared to accept a threshold value of Ki-67 within
the range of 20%–29% to distinguish ‘luminal B-like’ disease,
though about one-ﬁfth of the Panel felt that Ki-67 should not be
used at all for this distinction. Only a quarter of the Panel
believed that subtype determination could be replaced by risk
scores derived from multiparameter molecular markers.
A clear majority of the Panel did not accept the presence of
tumor-inﬁltrating lymphocytes (TILs) as either a prognostic or
predictive marker.
The Panel considered the role of multiparameter molecular
marker assays for prognosis separately in years 1–5 and beyond
5 years, and their value in selecting patients who require chemo-
therapy. Oncotype DX®, MammaPrint®, PAM-50 ROR® score,
EndoPredict®, and the Breast Cancer Index® were all considered
usefully prognostic for years 1–5. Beyond 5 years, the Panel was
divided almost equally on the prognostic value of Oncotype DX
(despite the available data from NSABP Trial B-14 [32]);
EndoPredict® (despite the report of Dubsky et al. [36]); and
Breast Cancer Index (despite the report of Zhang et al. [37]).
(All these reports show the respective tests to be prognostic
beyond 5 years.) PAM50 ROR® score was agreed to be clearly
prognostic beyond 5 years, and a clear majority rejected the
prognostic value of MammaPrint® in this time period. Only
Oncotype DX® commanded a majority in favor of its value in
predicting the usefulness of chemotherapy. Clinically, tests
which are prognostic, but not speciﬁcally predictive of the efﬁ-
cacy of cytotoxic therapy, are commonly used to make decisions
about such therapy. This is done on the grounds that they may
deﬁne a group of patients with a prognosis so good that even
if chemotherapy were similarly proportionately effective as in
higher risk patients the absolute beneﬁt may be thought insufﬁ-
cient to justify such treatment. Similarly, a test result indicating
a worse prognosis may be used to justify the use of effective but
more toxic endocrine therapy such as OFS plus AI or more
intensive or prolonged chemotherapy.
adjuvant endocrine therapy of premenopausal
patients
In the light of recently published results from the SOFT and
TEXT trials, the Panel considered treatment recommendations
for two clinical scenarios. The ﬁrst involved a 42-year-old
patient with node-negative, grade 2, T1, ER-positive tumor not
receiving chemotherapy. A large majority of the Panel would
treat such a patient with tamoxifen alone. The second scenario
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involved a 34-year-old patient with lymph node-positive, grade 3,
T1, ER-positive disease who remained premenopausal after adju-
vant chemotherapy. An overwhelming majority of the Panel
would advise OFS for this patient, and a large majority would use
this with exemestane rather than tamoxifen.
More generally, the Panel considered that factors arguing for
inclusion of OFS were age 35 or less; persisting premenopausal
estrogen level after adjuvant chemotherapy; or the involvement
of four or more axillary nodes. A lesser majority would add
grade 3 disease or an adverse result from a multiparameter
molecular marker test as indications for OFS.
Factors arguing for the use of an AI plus OFS rather than
tamoxifen plus OFS were (overwhelmingly) the involvement of
four or more nodes, with lesser majorities accepting age 35 or
less; grade 3; or the adverse result of a multiparameter molecular
marker test as supporting such treatment. The Panel was almost
evenly divided as to whether a persisting premenopausal estro-
gen level after adjuvant chemotherapy should favor an AI rather
than tamoxifen. As a supplementary question, the Panel was
asked, ‘if you decide to give OFS are you more likely to recom-
mend tamoxifen or an AI?’ with a majority favoring AI.
The Panel considered that if OFS were included the optimal
duration of such therapy should be 5 years, and that extended
endocrine therapy for a total of 10 years should be considered
for premenopausal patients initially node-positive or with other
adverse pathology.
adjuvant endocrine therapy of postmenopausal
patients
The Panel was almost unanimous that some postmenopausal
patients can be treated with tamoxifen alone. However, virtually
all Panel members regarded the involvement of four or more
nodes; grade 3 pathology; or high Ki-67 as arguing for the inclu-
sion of an AI at some point. A lesser majority also felt that
HER2 positivity argued in favor of inclusion of an AI, but the
Panel did not consider that age <60 should indicate AI therapy.
If an AI is used, the Panel was virtually unanimous that it
should start up front in patients at higher risk, while the Panel
was evenly divided on whether it should be used up front in all
patients. The Panel was comfortable to contemplate switching
from an AI to tamoxifen after 2 years if necessary.
The Panel was virtually unanimous that following 5 years
of adjuvant tamoxifen, patients with initially node-positive
disease should continue endocrine therapy to 10 years regardless
of menopausal status, but did not consider such extension
indicated for initially node-negative disease. A clear majority
favored extension to 10 years for patients with grade 3 tumors;
high Ki-67; and for patients premenopausal at baseline who
became postmenopausal during 5 years of tamoxifen.
The Panel then considered the more complex situation of
patients whose initial 5 years of adjuvant therapy had involved a
switch from tamoxifen to an AI. A clear majority was in favor of
continuing AI therapy to a total cumulative AI duration of 5 years.
Following initial therapy consisting of 5 years of a straight AI,
the Panel was evenly divided between recommendations for 3–5
years of tamoxifen; 3–5 more years of an AI; or no further endo-
crine treatment.
adjuvant cytotoxic chemotherapy
Pending the results of ongoing randomized trials, and notwith-
standing the Oxford Overview results [113], the Panel was strong-
ly of the opinion that relative indications for inclusion of adjuvant
cytotoxic chemotherapy for patients with ‘luminal’ disease types
were grade 3 histology; 4 or more positive nodes; low hormone re-
ceptor staining; high Ki-67; and extensive lymphovascular inva-
sion, but the majority did not believe that one to three positive
nodes or age <35 were indications for such treatment.
A clear majority of the Panel believed that ‘luminal A-like’
phenotype was less responsive to chemotherapy. They would not
add such treatment based on T size; lymphovascular invasion; or
the involvement of one to three lymph nodes in such patients.
However, the Panel almost unanimously recommended chemo-
therapy when four or more nodes are involved, presumably since
the risk of undertreatment is deemed greater in such patients.
The Panel did not believe that chemotherapy should be recom-
mended in all patients with ‘luminal B-like’ disease. Speciﬁcally, it
could be omitted in cases with low scores on Oncotype DX®;
MammaPrint®; PAM-50 ROR® score; or EndoPredict®. The Panel
was evenly divided about whether intermediate Oncotype DX®
score should be regarded as an indication for chemotherapy.
When cytotoxic chemotherapy is indicated for luminal disease,
the speciﬁc choice of regimen depends on the position within the
spectrum of degree of endocrine responsiveness and risk of
relapse. On average, for ‘luminal B-like’ tumors, the Oxford over-
view supports the inclusion of both an anthracycline and a taxane
[113], while in ‘luminal A-like’ tumors, there is little evidence of
an advantage compared with older regimens such as AC and
CMF [114]. If given, chemotherapy for ‘luminal B-like’ disease
should not extend beyond four courses of the same treatment, es-
pecially, for patients with a lower burden of disease. The addition
of taxanes should be considered for patients with more extensive
disease burden. A slim majority considered that there was a high-
risk group for which dose-dense therapy with G-CSF support
should be preferred.
In triple-negative disease, the Panel considered that the
chemotherapy should include an anthracycline and a taxane.
Despite the lack of randomized trial evidence, the Panel would
consider a platinum-based regimen in the presence of BRCA
mutation, but a large majority felt that standard anthracycline
and taxane-based therapy was appropriate for such patients.
Platinum-based therapy should not be routinely used in patients
without BRCA mutation. The Panel was divided about the value
of dose-dense therapy with growth factor support.
In patients with HER2-positive, stage 2 disease, the Panel was
almost unanimous that chemotherapy was required and should
in general contain an anthracycline and a taxane, with the anti-
HER2 therapy starting concurrent with the taxane.
The Panel next considered patients with stage 1, HER2-posi-
tive disease. A clear majority felt that anti-HER2 therapy was
not required in patients with T1a disease, while a large major-
ity would include such treatment of T1b, and all Panel
members would treat patients with T1c disease. A clear major-
ity of the Panel was willing to accept the combination of pacli-
taxel and trastuzumab without anthracycline as a reasonable
option for stage 1 patients and a maximum tumor diameter of
1 cm thought to require therapy. The Panel was divided about
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whether such treatment was appropriate for stage 1 patients
with a tumor >1 cm, with a slim majority favoring anthracy-
cline/taxane-based therapy for such patients.
adjuvant anti-HER2 therapies
Pending results from the ongoing APHINITY trial, the Panel
did not support dual HER2 blockade by the addition of either
pertuzumab or lapatinib to trastuzumab for postoperative adju-
vant therapy.
neoadjuvant cytotoxic chemotherapy for luminal
disease
The Panel did not generally support neoadjuvant cytotoxic
therapy for patients with ‘luminal A-like’ tumors, but would
contemplate it if conservative surgery would not otherwise be
feasible. In patients with ‘luminal B-like’ (HER2-negative)
tumors, the Panel was more closely divided, but only a minority
would recommend such treatment for the majority of cases.
neoadjuvant systemic therapy for stage 2
HER2-positive disease
The majority of the Panel supported dual anti-HER2 therapy
with taxane, trastuzumab, and pertuzumab as ‘an acceptable
regimen’ for such patients.
neoadjuvant systemic therapy for patients with
triple-negative tumours
The clear majority of the Panel favored anthracycline and
taxane-based treatment of such patients, and would not support
the use of high-dose alkylating agents or platinums. (The Panel
was not asked speciﬁcally about neoadjuvant platinum-based
therapy in the presence of known BRCA mutation, but later
agreed that such therapy should not be routinely used for
patients without BRCA mutation.)
neoadjuvant endocrine therapies
The Panel was strongly of the opinion that neoadjuvant endocrine
therapy without cytotoxics was a reasonable option for postmeno-
pausal patients with endocrine responsive disease. Indeed, the
Panel considered that the preferred treatment of postmenopausal
women with ‘luminal A-like’ breast cancer not suitable for breast-
conserving surgery at diagnosis was endocrine rather than cytotoxic
neoadjuvant therapy. The Panel considered that such treatment
should continue for either 4–8 months or until maximal response.
bisphosphonates
The Panel was divided about the use of bisphosphonates such as
zoledronic acid or clodronate to improve disease-free survival. In
postmenopausal patients, a slim majority would support such
treatment. Only a minority would support such treatment in pre-
menopausal patients receiving LHRH and tamoxifen. The Panel
was virtually unanimous in rejecting such treatment of premeno-
pausal patients not receiving LHRH and would not support the
use of denosumab as a substitute for bisphosphonates.
elderly patients
The Panel considered that there was no absolute age limit for
the use of standard chemotherapy regimens. Rather, the use of
such treatments should depend on disease characteristics, co-
morbidity, life expectancy, and patient preference.
Similarly, the Panel considered that there was no age at which
radiation therapy otherwise indicated should be omitted.
young patients
The Panel considered that testing for BRCA 1 and BRCA 2
mutations is indicated in patients aged <40 years and those with
a strong family history, but was divided about whether this
should be extended to testing for high-risk mutations in other
genes. The Panel would extend testing to patients up to the age
of 50 with triple-negative disease even in the absence of a family
history.
The Panel considered that fertility preservation by ovarian
tissue or oocyte conservation should be offered upon request for
patients aged <40.
The Panel strongly supported the use of OFS during chemo-
therapy for receptor-negative disease to preserve ovarian func-
tion and fertility.
high-risk mutations
The presence of a BRCA 1 or BRCA 2 mutation was thought to
inﬂuence locoregional and neoadjuvant treatment, but not adju-
vant therapy.
breast cancer diagnosed during pregnancy
For patients whose breast cancer was diagnosed during preg-
nancy premature delivery should be avoided if possible, and
standard chemotherapy regimens should be offered during the
third or second trimester, but not anti-HER-2 or endocrine
therapies. The Panel considered that breast conservation was a
suitable option; that sentinel node biopsy using radioisotope
was safe; and that immediate post mastectomy reconstruction
could be considered.
attempting pregnancy after breast cancer
The Panel acknowledged the possibility of interrupting endo-
crine therapy after 18–30 months to allow attempted pregnancy,
but only in the absence of high-risk features.
male breast cancer
Recognizing that the current adjuvant treatment of males with
breast cancer is tamoxifen, the Panel did not support the use of
AIs, either with or without LHRH agonists.
lifestyle factors to reduce the risk of recurrence
The Panel supported the use of an exercise regimen and weight
loss (or at least avoidance of weight gain). They did not recom-
mend any speciﬁc dietary advice to improve prognosis, but a
majority would support vitamin D supplementation for those
shown to be vitamin D deﬁcient.
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summary of treatment recommendations
surgery
Meta-analysis of surgical series showed no further beneﬁt from
margins beyond ‘no ink on invasive tumor or DCIS’, including
patients with lobular histology, extensive intraductal compo-
nent, young age, or unfavorable biological subtype.
Axillary dissection can be avoided for patients with one or
two macrometastatic lymph nodes.
radiotherapy
Disease control and survival are improved when radiation ﬁelds
were extended to include regional lymph node areas in patients
with node-positive disease.
neoadjuvant systemic therapies
While acknowledging that neoadjuvant therapy has not been
shown to produce survival outcomes superior to those of post-
operative adjuvant therapy alone, there is increasing support for
neoadjuvant cytotoxic therapy in Stage II triple-negative disease
and for combined chemotherapy and anti-HER2 therapy in
patients with HER2-positive disease and large tumors. In patients
with luminal disease, there is less indication for neoadjuvant
cytotoxic chemotherapy unless it is given to enable breast con-
servation, but the option of neoadjuvant endocrine therapy also
exists for many of these patients.
postoperative systemic adjuvant therapies
As summarized in Tables 2 and 3, most patients with triple-
negative disease should receive cytotoxic chemotherapy contain-
ing an anthracycline and a taxane, though a slim majority of the
Panel felt that platinum-based therapy might be considered for
a patient with known BRCA mutation.
In patients with HER2-positive, node-negative disease and
T-size <2 cm, a nonanthracycline regimen comprising paclitaxel
and 1 year of trastuzumab is appropriate, while for more exten-
sive disease treatment should commence with anthracycline and
be followed by concurrent taxane and trastuzumab, with the
trastuzumab continued for a total of 1 year.
Patients with hormone receptor-positive and HER2-positive
disease will require endocrine therapy appropriate to their meno-
pausal status in addition to cytotoxics and anti-HER2 therapy.
For patients with hormone receptor-positive and HER2-
negative disease, a spectrum exists in degree of risk and of re-
sponsiveness to cytotoxic chemotherapy. Those at lower risk
with strongly positive receptors can be adequately treated with
endocrine therapy alone. Consideration of the relative level of
hormone receptor expression and proliferation are important to
determine prognosis and the need for adjuvant chemotherapy.
The multiparameter assays, either immunohistochemically based
‘IHC4’ as carried out by Cuzick and Dowsett or one of several
multiparameter molecular marker assays, such as OncotypeDx®,
MammaPrint®, Endopredict®, PAM50 ROR®, and BCI®, each
appears to identify a group of patients for whom prognosis is so
favorable that even if chemotherapy is effective, the beneﬁts of
treatment are so small that they do not outweigh the risks. For
patients with worse anatomical prognostic features, such as the
presence of a T4 lesion, high Ki-67, low hormone receptor staining
or four or more positive axillary lymph nodes, even those with fa-
vorable multiparameter molecular assay results may have a sufﬁ-
ciently high risk of recurrence to justify adjuvant chemotherapy.
Endocrine therapy for premenopausal patients at low risk
should comprise tamoxifen for 5 years, while those at higher
risk should be considered for OFS and the substitution of exe-
mestane for tamoxifen. In patients who have completed 5 years
of adjuvant tamoxifen therapy and are regarded as being at
higher risk, it is appropriate to consider continuing endocrine
Table 2. Treatment-oriented classification of subgroups of breast cancer
Clinical grouping Notes
Triple-negative Negative ER, PgR, and HER2
Hormone receptor-negative and HER2-positive ASCO/CAP guidelines
Hormone receptor-positive and HER2-positive ASCO/CAP guidelines
Hormone receptor-positive and HER2-negative
luminal disease as a spectrum:
ER and/or PgR positive1%a
High receptor, low proliferation, low tumor
burden (luminal A-like)
Multiparameter molecular marker ‘favorable prognosis’ if available. High ER/PgR and
clearly low Ki-67b. Low or absent nodal involvement (N 0–3), smaller T size (T1 T2).
Intermediate Multiparameter molecular marker ‘intermediate’ if availablec.
Uncertainty persists about degree of risk and responsiveness to endocrine and
cytotoxic therapies.
Low receptor, high proliferation, high tumor
burden (luminal B-like)
Multiparameter molecular marker ‘unfavorable prognosis’ if available. Lower ER/PgR
with clearly high Ki-67b. More extensive nodal involvement, histological grade 3,
extensive lymphovascular invasion, larger T size (T3).
aER values between 1% and 9% were considered equivocal. Thus, endocrine therapy alone cannot be relied upon for patients with these values.
bKi-67 scores should be interpreted in the light of local laboratory values: as an example, if a laboratory has a median Ki-67 score in receptor-positive
disease of 20%, values of 30% or above could be considered clearly high; those of 10% or less clearly low.
cNot all multiparameter molecular marker tests report an intermediate score.
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therapy for a total of 10 years using either further tamoxifen or,
if the patient is clearly postmenopausal, an AI.
For patients postmenopausal at presentation, tamoxifen alone
may be suitable for those at lower risk while, for other patients,
an AI should be considered and given up front, especially in
those at higher risk.
Many patients now receive an AI for all or part of their ﬁrst 5
years of endocrine therapy. While there is less evidence to guide
extended endocrine therapy in such patients, continuation of an
AI to a cumulative exposure of 5 years seems appropriate. There
is no evidence about the safety or efﬁcacy of longer periods of AI
therapy, but studies of such treatment are in progress.
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